Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
This demonstrates that injectable GHK-Cu creates systemic enhancement, meaning it does not just work where you inject it
The approval was based on data from the FIBRONEER-IPF trial, where the drug showed: A smaller decline in Forced Vital Capacity (FVC) over 52 weeks versus placebo Benefits visible as early as week 2 A favourable safety profile A huge milestone for patients living with IPF
Copyright: 2024, Chen et al
How TB-500 Works: The Systemic Mechanism Behind the Protocol TB-500s therapeutic effects operate through three primary pathways that inform how the protocol is structured: Actin regulation: Thymosin Beta-4 binds to G-actin (monomeric actin) and regulates its availability for polymerization
US$ 28.13
US$ 22.34
US$ 25.63
